Conceptualization, C.T., Y.R., C.C.J., S.A.M., M.A.M., P.V., P.C.A., N.L., W.K., P.P., S.T., P.K., P.N., M.C. and W.C.; Data curation, C.T. and N.L.; Formal analysis, C.T. and W.C.; Funding acquisition, W.C.; Investigation, C.T., Y.R., P.V., W.K. and W.C.; Methodology, C.T., Y.R., S.A.M., P.P., S.T., P.K., P.N., M.C. and W.C.; Project administration, S.A.M., M.A.M., P.C.A., N.L., S.T., P.N., M.C. and W.C.; Resources, W.C.; Software, W.C.; Supervision, C.T., C.C.J., S.A.M., M.A.M., P.P., M.C. and W.C.; Validation, C.T., Y.R., C.C.J., W.K., P.K. and W.C.; Visualization, C.T., Y.R., P.P. and W.C.; Writing—original draft, C.T., Y.R. and W.C.; Writing—review and editing, C.T., Y.R., C.C.J., S.A.M., M.A.M., P.V., P.C.A., N.L., W.K., P.P., S.T., P.K., P.N., M.C. and W.C. All authors have read and agreed to the published version of the manuscript.

Figure 1. (A). CDF plot displaying consensus distributions for each k; (B). Delta area plot reflecting the relative changes in the area under the CDF curve. (C). Consensus matrix heat map depicting consensus values on a white to blue color scale of each cluster.

Figure 1. (A). CDF plot displaying consensus distributions for each k; (B). Delta area plot reflecting the relative changes in the area under the CDF curve. (C). Consensus matrix heat map depicting consensus values on a white to blue color scale of each cluster.

Figure 2. The bar plot represents the mean consensus score for different numbers of clusters (from two to ten). Different colors indicate different cluster groups.

Figure 2. The bar plot represents the mean consensus score for different numbers of clusters (from two to ten). Different colors indicate different cluster groups.

Figure 3. (A). The standardized differences across cluster 1 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (B). The standardized differences across cluster 2 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (C). The standardized differences across cluster 3 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (D). The standardized differences across cluster 4 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (E). The standardized differences across cluster 5 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (F). The standardized differences across cluster 6 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient.

Figure 3. (A). The standardized differences across cluster 1 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (B). The standardized differences across cluster 2 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (C). The standardized differences across cluster 3 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (D). The standardized differences across cluster 4 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (E). The standardized differences across cluster 5 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient. (F). The standardized differences across cluster 6 for each of baseline parameters. The x axis is the standardized differences value, and the y axis shows baseline parameters. The dashed vertical lines represent the standardized differences cutoffs of <−0.3 or >0.3. Abbreviations: BMI: Body mass index, CMV: Cytomegalovirus, D: Donor, DGF: Delayed graft function, DM: diabetes mellitus, EBV: Epstein–Barr virus, ECD: Extended criteria donor, ESKD: end stage kidney disease, GN: Glomerulonephritis, HBs: Hepatitis B surface, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, HLA: Human leucocyte antigen, HTN: Hypertension, KDPI: Kidney donor profile index, mTOR: Mammalian target of rapamycin, PKD: Polycystic kidney disease, PRA: Panel reactive antibody, PVD: peripheral vascular disease, R: Recipient.

Figure 4. Proportion of the assigned clusters based on the UNOS regions.

Figure 4. Proportion of the assigned clusters based on the UNOS regions.

Figure 5. (A). Patient survival after kidney transplant from high KDPI deceased donors in the U.S. (B). Death-censored graft survival after kidney transplant from high KDPI deceased donors in the U.S. (C). Death-censored graft survival after kidney transplant from high KDPI deceased donors in the U.S.

Figure 5. (A). Patient survival after kidney transplant from high KDPI deceased donors in the U.S. (B). Death-censored graft survival after kidney transplant from high KDPI deceased donors in the U.S. (C). Death-censored graft survival after kidney transplant from high KDPI deceased donors in the U.S.

Table 1. Clinical characteristics according to clusters.

Table 1. Clinical characteristics according to clusters.

All
(n = 8935)Cluster 1
(n = 1984)Cluster 2
(n = 2135)Cluster 3
(n = 357)Cluster 4
(n = 335)Cluster 5
(n = 1069)Cluster 6
(n = 3055)p-ValueRecipient age (year)62.4 ± 9.557.2 ± 9.968.0 ± 6.957.3 ± 11.051.7 ± 13.763.3 ± 8.763.3 ± 7.2<0.001Recipient male sex5699 (63.8)1213 (61.1)1371 (64.2)223 (62.5)170 (50.8)598 (55.9)2124 (69.5)<0.001Recipient race
-

White

-

Black

-

Hispanic

-

Other

3341 (37.4)
3080 (34.5)
1549 (17.3)
965 (10.8)
204 (10.3)
1298 (65.4)
308 (15.5)
174 (8.8)
1554 (72.7)
200 (9.4)
185 (8.7)
196 (9.2)
163 (45.6)
130 (36.4)
32 (9.0)
32 (9.0)
85 (25.3)
82 (24.5)
71 (21.2)
97 (28.9)
510 (47.7)
260 (24.3)
213 (19.9)
86 (8.1)
825 (27.0)
1110 (36.3)
740 (24.2)
380 (12.5)<0.001ABO blood group
-

A

-

B

-

AB

-

O

2846 (31.9)
1374 (15.4)
340 (3.8)
4375 (48.9)
377 (19.0)
392 (19.8)
61 (3.1)
1154 (58.1)
903 (42.3)
222 (10.4)
79 (3.7)
931 (43.6)
112 (31.4)
63 (17.7)
18 (5.0)
164 (45.9)
87 (26.0)
69 (20.6)
15 (4.5)
164 (48.9)
381 (35.6)
145 (13.6)
40 (3.7)
503 (47.1)
986 (32.3)
483 (15.8)
127 (4.2)
1459 (47.7)<0.001Body mass index (kg/m2)28.5 ± 5.028.6 ± 5.327.3 ± 4.727.4 ± 5.424.8 ± 4.128.7 ± 5.029.6 ± 4.8<0.001Kidney retransplant364 (4.1)0 (0)0 (0)357 (100)7 (2.1)0 (0)0 (0)<0.001Dialysis duration
-

Preemptive

-

<1 year

-

1–3 years

-

>3 years

803 (9.0)
2234 (25.0)
775 (8.7)
5123 (57.3)
99 (5.0)
315 (15.9)
107 (5.4)
1463 (73.7)
359 (16.8)
661 (31.0)
253 (11.9)
862 (40.4)
35 (9.8)
88 (24.7)
36 (10.1)
198 (55.5)
35 (10.5)
112 (33.4)
39 (11.6)
149 (44.5)
110 (10.3)
306 (28.6)
111 (10.4)
542 (50.7)
165 (5.4)
752 (24.6)
229 (7.5)
1909 (62.5)<0.001Cause of end-stage kidney disease
-

Diabetes mellitus

-

Hypertension

-

Glomerular disease

-

PKD

-

Other

3623 (40.5)
2525 (28.3)
1104 (12.4)
602 (6.7)
1081 (12.1)
18 (0.9)
1318 (66.4)
328 (16.5)
164 (8.3)
156 (7.9)
61 (2.9)
784 (36.7)
489 (22.9)
292 (13.7)
509 (23.8)
32 (9.0)
61 (17.1)
48 (13.5)
14 (3.9)
202 (56.5)
80 (23.9)
89 (26.5)
76 (22.7)
30 (9.0)
60 (17.9)
460 (43.0)
253 (23.7)
139 (13.0)
84 (7.9)
133 (12.4)
2972 (97.2)
20 (0.7)
24 (0.8)
18 (0.6)
21 (0.7)<0.001Comorbidity
-

Diabetes mellitus

-

Malignancy

-

Peripheral vascular disease

4484 (50.2)
975 (10.9)
987 (11.1)
331 (16.7)
123 (6.2)
107 (5.4)
314 (14.7)
419 (19.6)
148 (6.9)
116 (32.5)
49 (13.7)
30 (8.4)
101 (30.2)
32 (9.6)
18 (5.4)
567 (53.0)
129 (12.1)
119 (11.1)
3055 (100.0)
223 (7.3)
565 (18.5)
<0.001
<0.001
<0.001PRA (%), median (IQR)0 (0–1)0 (0–4)0 (0–0)48 (0–95)0 (0–0)0 (0–17)0 (0–0)<0.001Positive HCV serostatus455 (5.1)145 (7.3)70 (3.3)34 (9.5)9 (2.7)47 (4.4)150 (4.9)<0.001Positive HBs antigen181 (2.0)43 (2.2)30 (1.4)14 (3.9)16 (4.8)24 (2.3)54 (1.8)<0.001Positive HIV serostatus63 (0.7)31 (1.6)9 (0.4)0 (0.0)4 (1.2)5 (0.5)14 (0.5)<0.001Functional status
-

10–30%

-

40–70%

-

80–100%

26 (0.3)
3723 (41.7)
5186 (58.0)
4 (0.2)
859 (43.3)
1121 (56.5)
6 (0.3)
709 (33.2)
1420 (66.5)
0 (0.0)
143 (40.1)
214 (59.9)
2 (0.6)
101 (30.2)
232 (69.2)
3 (0.3)
429 (40.1)
637 (59.6)
11 (0.4)
1482 (48.5)
1562 (51.1)<0.001Working income1593 (17.8)415 (20.9)427 (20.0)71 (19.9)100 (29.8)192 (18.0)388 (12.7)<0.001Public insurance7320 (81.9)1676 (84.5)1672 (78.3)297 (83.2)232 (69.3)865 (80.9)2578 (84.4)<0.001US resident8872 (99.3)1966 (99.1)2127 (99.6)356 (99.7)323 (96.4)1060 (99.2)3040 (99.5)<0.001Undergraduate education or above4400 (49.2)863 (43.5)1274 (59.7)188 (52.7)188 (56.1)530 (49.6)1357 (44.4)<0.001Serum albumin (g/dL)3.9 ± 0.54.0 ± 0.54.0 ± 0.53.8 ± 0.64.0 ± 0.53.9 ± 0.53.9 ± 0.6<0.001Kidney donor status
-

Non-ECD deceased

-

ECD deceased

1673 (18.7)
7262 (81.3)
484 (24.4)
1500 (75.6)
184 (8.6)
1951 (91.4)
80 (22.4)
277 (77.6)
335 (100)
0 (0)
155 (14.5)
914 (85.5)
435 (14.2)
2620 (85.8)<0.001Donor age (year)58.3 ± 13.258.1 ± 6.662.6 ± 6.358.4 ± 8.40.7 ± 3.161.1 ± 6.960.7 ± 6.7<0.001Donor male sex4124 (46.2)850 (42.8)944 (44.2)165 (46.2)189 (56.4)515 (48.2)1461 (47.8)<0.001Donor race
-

White

-

Black

-

Hispanic

-

Other

4532 (50.7)
2928 (32.7)
987 (11.1)
488 (5.5)
605 (30.5)
1042 (52.5)
208 (10.5)
129 (6.5)
1472 (68.9)
367 (17.2)
198 (9.3)
98 (4.6)
158 (44.3)
139 (38.9)
35 (9.8)
25 (7.0)
104 (31.0)
191 (57.0)
32 (9.6)
8 (2.4)
677 (63.3)
206 (19.3)
138 (12.9)
48 (4.5)
1516 (49.6)
983 (32.2)
376 (12.3)
180 (5.9)<0.001Donor weight (kg)79 ± 2682 ± 2382 ± 2281 ± 239 ± 981 ± 2383 ± 22<0.001Donor Height (cm)163 ± 22167 ± 10167 ± 10167 ± 1367 ± 17167 ± 11168 ± 10<0.001Donor hypertension 6833 (76.5)1633 (82.3)1648 (77.2)287 (80.4)6 (1.8)837 (78.3)2422 (79.3)<0.001Donor diabetes 2416 (27)571 (29)588 (28)93 (26)3 (1)306 (29)855 (28)<0.001Donor positive HCV serostatus 387 (4)110 (6)71 (3)28 (8)2 (1)45 (4)131 (4)<0.001Donor cerebrovascular death6142 (69)1469 (74)1489 (70)257 (72)14 (4)744 (70)2169 (71)<0.001Donor creatinine (mg/dL)1.3 ± 1.01.3 ± 0.0.71.3 ± 1.11.3 ± 0.61.0 ± 1.81.3 ± 1.11.3 ± 0.8<0.001KDPI (%)91 ± 491 ± 491 ± 490 ± 489 ± 491 ± 491 ± 4<0.001Dual kidney transplant840 (9.4)94 (4.7)189 (8.9)10 (2.8)280 (83.6)77 (7.2)190 (6.2)<0.001Total HLA mismatch, median (IQR)5 (4-5)5 (4-6)5 (4-5)4 (3-5)5 (4-6)3 (2-3)5 (4-6)<0.001Cold ischemia time (hours)20.2 ± 9.019.6 ± 9.020.5 ± 9.120.4 ± 9.121.7 ± 8.719.7 ± 8.420.4 ± 9.0<0.001Kidney on pump5428 (60.8)1171 (59.0)1400 (65.6)206 (57.7)143 (42.7)623 (58.3)1885 (61.7)<0.001Allocation type
-

Local

-

Regional

-

National

5248 (58.7)
2264 (25.3)
1423 (16.0)
1298 (65.4)
452 (22.8)
234 (11.8)
1269 (59.4)
531 (24.9)
335 (15.7)
169 (47.3)
86 (24.1)
102 (28.6)
86 (25.7)
101 (30.1)
148 (44.2)
608 (56.9)
261 (24.4)
200 (18.7)
1818 (59.5)
833 (27.3)
404 (13.2)<0.001EBV status
-

Low risk

-

Moderate risk

-

High risk

23 (0.3)
8197 (91.7)
715 (8.0)
2 (0.1)
1847 (93.1)
135 (6.8)
8 (0.4)
1916 (89.7)
211 (9.9)
0 (0)
327 (91.6)
30 (8.4)
9 (2.7)
316 (94.3)
10 (3.0)
1 (0.1)
979 (91.6)
89 (8.3)
3 (0.1)
2812 (92.0)
240 (7.9)<0.001CMV status
-

D−/R−

-

D−/R+

-

D+/R+

-

D+/R−

722 (8.1)
1711 (19.1)
4777 (53.5)
1725 (19.3)
68 (3.4)
254 (12.8)
1369 (69.0)
293 (14.8)
270 (12.7)
468 (21.9)
796 (37.3)
601 (28.1)
28 (7.8)
70 (19.6)
196 (54.9)
63 (17.7)
25 (7.5)
151 (45.1)
116 (34.6)
43 (12.8)
109 (10.2)
196 (18.3)
529 (49.5)
235 (22.0)
222 (7.3)
572 (18.7)
1771 (58.0)
490 (16.0)<0.001Induction immunosuppression
-

Thymoglobulin

-

Alemtuzumab

-

Basiliximab

-

Other

-

No induction

5021 (56.2)
1382 (15.5)
2080 (23.3)
256 (2.9)
687 (7.7)
1130 (57.0)
342 (17.2)
386 (19.5)
82 (4.1)
170 (8.6)
1079 (50.5)
342 (16.0)
622 (29.1)
53 (2.5)
161 (7.5)
211 (59.1)
57 (16.0)
51 (14.3)
16 (4.5)
34 (9.5)
268 (80.0)
22 (6.6)
33 (9.8)
10 (3.0)
13 (3.9)
577 (54.0)
176 (16.5)
258 (24.1)
29 (2.7)
82 (7.7)
1756 (57.5)
443 (14.5)
730 (23.9)
66 (2.2)
227 (7.4)
<0.001
<0.001
<0.001
<0.001
0.050Maintenance Immunosuppression
-

Tacrolimus

-

Cyclosporine

-

Mycophenolate

-

Azathioprine

-

mTOR inhibitors

-

Steroid

7983 (89.3)
115 (1.3)
8185 (91.6)
21 (0.2)
94 (1.1)
5910 (66.1)
1766 (89.0)
23 (1.2)
1821 (91.8)
1 (0.1)
20 (1.0)
1330 (67.0)
1896 (88.8)
31 (1.4)
1952 (91.4)
9 (0.4)
31 (1.5)
1341 (62.8)
312 (87.4)
6 (1.7)
323 (90.5)
2 (0.6)
4 (1.1)
258 (72.3)
298 (89.0)
4 (1.2)
307 (91.6)
1 (0.3)
1 (0.3)
160 (47.8)
954 (89.2)
15 (1.4)
962 (90.0)
2 (0.2)
11 (1.0)
736 (68.9)
2757 (90.2)
36 (1.2)
2820 (92.3)
6 (0.2)
27 (0.9)
2085 (68.3)
0.419
0.905
0.274
0.155
0.307
<0.001

Table 2. Post-transplant outcomes according to the clusters.

Table 2. Post-transplant outcomes according to the clusters.

Cluster 1Cluster 2Cluster 3Cluster 4Cluster 5Cluster 6Primary non-function36 (1.8%)26 (1.2%)5 (1.4%)4 (1.2%)7 (0.7%)31 (1.0%)Delayed graft function759 (38.3%)535 (25.1%)149 (41.7%)101 (30.2%)340 (31.8%)1247 (40.8%)1-year survival95.3%93.9%91.0%98.1%92.2%92.5%5-year survival79.2%68.6%62.1%90.5%68.9%67.0%1-year death-censored graft survival91.2%94.3%87.8%85.6%93.4%92.3%5-year death-censored graft survival73.1%84.3%70.1%81.8%80.5%76.2%1-year graft survival88.1%90.2%81.8%84.8%88.6%87.3%5-year graft survival63.9%64.2%53.2%76.9%63.4%58.9%1-year acute rejection157 (7.9%)134 (6.3%)38 (10.6%)8 (2.4%)69 (6.5%)200 (6.6%)